<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report a patient with <z:e sem="disease" ids="C0856536" disease_type="Neoplastic Process" abbrv="">Philadelphia chromosome positive</z:e> (Ph +ve) <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), treated with <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> alone, who upon disease progression developed an additional Ph - ve clone containing chromosomal abnormalities typical of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Retrospective analysis of a cryopreserved stem cell specimen from diagnosis confirmed that this second clone developed during the course of treatment </plain></SENT>
<SENT sid="2" pm="."><plain>The development of a clone with additional cytogenetic abnormalities in <z:mp ids='MP_0005481'>CML</z:mp> has only been reported after leukemogenic treatment, stem cell transplantation or interferon </plain></SENT>
<SENT sid="3" pm="."><plain>We report a case of secondary Ph - ve <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> during <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> in a patient treated with <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> for <z:mp ids='MP_0005481'>CML</z:mp> </plain></SENT>
</text></document>